Blog

Astellas Acquires Stem Cell Company Ocata Therapeutics At 90% Premium – What … – Seeking Alpha


Seeking Alpha

Astellas Acquires Stem Cell Company Ocata Therapeutics At 90% Premium – What
Seeking Alpha
While it is not worthwhile to do an in depth analysis of a stem cell company that will soon no longer operate independently, there are lessons to be learned and questions to be asked related to the acquisition and what it means to the stem cell sector
ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with PR Newswire (press release)



all 4 news articles »

2015-11-12
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.